{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:04:38Z","timestamp":1790615078475,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.neurol.2022.12.007","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T08:01:25Z","timestamp":1678348885000},"page":"337-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations"],"prefix":"10.1016","volume":"179","author":[{"given":"S.","family":"Auvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Baulac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurol.2022.12.007_bib0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neurol.2022.12.007_bib0285","first-page":"7","article-title":"Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation","author":"LaSarge","year":"2014","journal-title":"Front Mol Neuroscie"},{"issue":"7","key":"10.1016\/j.neurol.2022.12.007_bib0290","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.tcb.2014.03.003","article-title":"Regulation of mTORC1 by amino acids","volume":"24","author":"Bar-Peled","year":"2014","journal-title":"Trends Cell Biol"},{"issue":"6","key":"10.1016\/j.neurol.2022.12.007_bib0295","article-title":"\u201cmTORopathies: a road well-traveled\u201d","volume":"20","author":"Crino","year":"2020","journal-title":"Epilep Curr"},{"issue":"11","key":"10.1016\/j.neurol.2022.12.007_bib0300","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1474-4422(21)00265-9","article-title":"Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours","volume":"20","author":"Blumcke","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2022.12.007_bib0305","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Humn Gen"},{"issue":"7","key":"10.1016\/j.neurol.2022.12.007_bib0310","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/epi.12680","article-title":"Severity of manifestations in tuberous sclerosis complex in relation to genotype","volume":"55","author":"Kothare","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2022.12.007_bib0315","first-page":"8","article-title":"The genomic landscape of tuberous sclerosis complex","author":"Martin","year":"2017","journal-title":"Nat Communications"},{"issue":"5","key":"10.1016\/j.neurol.2022.12.007_bib0320","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2601","article-title":"Mutations of DEPDC5 cause autosomal dominant focal epilepsies","volume":"45","author":"Ishida","year":"2013","journal-title":"Nat Gen"},{"issue":"5","key":"10.1016\/j.neurol.2022.12.007_bib0325","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2599","article-title":"Mutations in DEPDC5 cause familial focal epilepsy with variable foci","volume":"45","author":"Dibbens","year":"2013","journal-title":"Nat Gen"},{"issue":"4","key":"10.1016\/j.neurol.2022.12.007_bib0330","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ana.24368","article-title":"Familial Focal Epilepsy with Focal Cortical Dysplasia Due to DEPDC5 Mutations","volume":"77","author":"Baulac","year":"2015","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2022.12.007_bib0335","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00401-019-02061-5","article-title":"Dissecting the genetic basis of focal cortical dysplasia: a large cohort study","volume":"138","author":"Baldassari","year":"2019","journal-title":"Acta Neuropathologica"},{"issue":"6","key":"10.1016\/j.neurol.2022.12.007_bib0340","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1172\/JCI99384","article-title":"Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy","volume":"128","author":"Ribierre","year":"2018","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.neurol.2022.12.007_bib0345","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.24126","article-title":"Mutations in Mammalian Target of Rapamycin Regulator DEPDC5 Cause Focal Epilepsy with Brain Malformations","volume":"75","author":"Scheffer","year":"2014","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2022.12.007_bib0350","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/epi.13391","article-title":"Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia","volume":"57","author":"Weckhuysen","year":"2016","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.neurol.2022.12.007_bib0355","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.24547","article-title":"Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy","volume":"79","author":"Ricos","year":"2016","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2022.12.007_bib0360","first-page":"398","article-title":"The landscape of epilepsy-related GATOR1 variants","volume":"21","author":"Baldassari","year":"2019","journal-title":"Gen Med"},{"issue":"1","key":"10.1016\/j.neurol.2022.12.007_bib0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuron.2012.03.010","article-title":"Somatic activation of AKT3 causes hemispheric developmental brain malformations","volume":"74","author":"Poduri","year":"2012","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.neurol.2022.12.007_bib0370","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.2329","article-title":"De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly","volume":"44","author":"Lee","year":"2012","journal-title":"Nat Gen"},{"issue":"4","key":"10.1016\/j.neurol.2022.12.007_bib0375","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022442","article-title":"mTOR signaling in epilepsy: insights from malformations of cortical development","volume":"5","author":"Crino","year":"2015","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"1","key":"10.1016\/j.neurol.2022.12.007_bib0380","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1528-1167.2010.02777.x","article-title":"The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission","volume":"52","author":"Blumcke","year":"2011","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.neurol.2022.12.007_bib0385","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41593-018-0257-3","article-title":"Somatic mosaicism and neurodevelopmental disease","volume":"21","author":"D\u2019Gama","year":"2018","journal-title":"Nat Neurosci"},{"issue":"6","key":"10.1016\/j.neurol.2022.12.007_bib0390","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00401-019-02052-6","article-title":"Precise detection of low-level somatic mutation in resected epilepsy brain tissue","volume":"138","author":"Sim","year":"2019","journal-title":"Acta Neuropathologica"},{"issue":"3","key":"10.1016\/j.neurol.2022.12.007_bib0395","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/brain\/awab376","article-title":"Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care","volume":"145","author":"Pirozzi","year":"2022","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurol.2022.12.007_bib0400","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/acn3.51286","article-title":"Gradient of brain mosaic RHEB variants causes a continuum of cortical dysplasia","volume":"8","author":"Lee","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2022.12.007_bib0405","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/acn3.50815","article-title":"Second-hit DEPDC5 mutation is limited to dysmorphic neurons in cortical dysplasia type IIA","volume":"6","author":"Lee","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2022.12.007_bib0410","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.phrs.2016.03.039","article-title":"mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis","volume":"107","author":"Citraro","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.neurol.2022.12.007_bib0415","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2016.11.017","article-title":"Molecular neurobiology of mTOR","volume":"341","author":"Switon","year":"2017","journal-title":"Neurosci"},{"key":"10.1016\/j.neurol.2022.12.007_bib0420","first-page":"15","article-title":"Convergent and divergent mechanisms of epileptogenesis in mTORopathies","author":"Nguyen","year":"2021","journal-title":"Front Neuroanat"},{"issue":"4","key":"10.1016\/j.neurol.2022.12.007_bib0425","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2022.12.007_bib0430","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/hmg\/ddq491","article-title":"Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of Tuberous Sclerosis Complex","volume":"20","author":"Zeng","year":"2011","journal-title":"Hum Mol Gen"},{"issue":"1","key":"10.1016\/j.neurol.2022.12.007_bib0435","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ana.26256","article-title":"Cardiac investigations in sudden unexpected death in DEPDC5-related epilepsy","volume":"91","author":"Bacq","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2022.12.007_bib0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.nbd.2017.12.010","article-title":"A mouse model of DEPDC5-related epilepsy: neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility","volume":"111","author":"Yuskaitis","year":"2018","journal-title":"Neurobiol Dis"},{"issue":"17","key":"10.1016\/j.neurol.2022.12.007_bib0445","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/hmg\/ddz123","article-title":"Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice","volume":"28","author":"Yuskaitis","year":"2019","journal-title":"Hum Mol Gen"},{"key":"10.1016\/j.neurol.2022.12.007_bib0450","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nbd.2016.02.010","article-title":"Depdc5 knockout rat: a novel model of mTORopathy","volume":"89","author":"Marsan","year":"2016","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.neurol.2022.12.007_bib0455","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nm.3824","article-title":"Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy","volume":"21","author":"Lim","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2022.12.007_bib0460","first-page":"7","article-title":"Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement","author":"Hsieh","year":"2016","journal-title":"Nat Com"},{"issue":"7\u20138","key":"10.1016\/j.neurol.2022.12.007_bib0465","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1242\/dmm.002386","article-title":"Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia","volume":"2","author":"Ljungberg","year":"2009","journal-title":"Dis Mod Mech"},{"issue":"8","key":"10.1016\/j.neurol.2022.12.007_bib0470","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/hmg\/ddaa068","article-title":"Prevention of premature death and seizures in a Depdc5 mouse epilepsy model through inhibition of mTORC1","volume":"29","author":"Klofas","year":"2020","journal-title":"Hum Mol Gen"},{"issue":"5","key":"10.1016\/j.neurol.2022.12.007_bib0480","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"issue":"10056","key":"10.1016\/j.neurol.2022.12.007_bib0475","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.neurol.2022.12.007_bib0485","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurol"},{"issue":"12","key":"10.1016\/j.neurol.2022.12.007_bib0490","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1111\/epi.17099","article-title":"Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3","volume":"62","author":"Franz","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2022.12.007_bib0500","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.seizure.2021.10.011","article-title":"Long-term treatment with everolimus in TSC-associated therapy-resistant epilepsies","volume":"93","author":"Wiegand","year":"2021","journal-title":"Seizure-Eur J Epilep"},{"key":"10.1016\/j.neurol.2022.12.007_bib0510","first-page":"13","article-title":"Antiepileptic effect and safety profile of rapamycin in pediatric patients with tuberous sclerosis complex","author":"Sadowski","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2022.12.007_bib0515","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.seizure.2020.03.018","article-title":"Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study","volume":"79","author":"He","year":"2020","journal-title":"Seizure-Eur J Epilep"},{"issue":"2","key":"10.1016\/j.neurol.2022.12.007_bib0530","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/acn3.51505","article-title":"Sirolimus for epileptic seizures associated with focal cortical dysplasia type II","volume":"9","author":"Kato","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2022.12.007_bib0495","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2352-4642(18)30099-3","article-title":"Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial","volume":"2","author":"Curatolo","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"11","key":"10.1016\/j.neurol.2022.12.007_bib0505","article-title":"Compassionate use of everolimus for refractory epilepsy in a patient with MTOR mosaic mutation","volume":"63","author":"Hadouiri","year":"2020","journal-title":"Eur J Med Gen"},{"issue":"6","key":"10.1016\/j.neurol.2022.12.007_bib0520","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ejpn.2018.06.007","article-title":"Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience","volume":"22","author":"Krueger","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2022.12.007_bib0525","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/0883073818813238","article-title":"mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: a case report","volume":"34","author":"Xu","year":"2019","journal-title":"J Child Neurol"},{"issue":"7711","key":"10.1016\/j.neurol.2022.12.007_bib0535","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurol.2022.12.007_bib0540","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01745-0","article-title":"Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome","volume":"16","author":"Forde","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"7928","key":"10.1016\/j.neurol.2022.12.007_bib0545","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41586-022-05213-y","article-title":"Brain-restricted mTOR inhibition with binary pharmacology","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurol.2022.12.007_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.braindev.2018.07.003","article-title":"Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan","volume":"41","author":"Mizuguchi","year":"2019","journal-title":"Brain Develop"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:46:39Z","timestamp":1758519999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378723008676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0035378723008676"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.12.007","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}